A Look At Alnylam Pharmaceuticals (ALNY) Valuation After New Cardiovascular Data And Partnerships At ACC.26

Alnylam Pharmaceuticals (ALNY) has drawn fresh attention after presenting extensive cardiovascular data at ACC.26. The company highlighted vutrisiran in amyloidosis and zilebesiran in hypertension, alongside new efforts to improve ATTR-CM diagnosis and care coordination.

See our latest analysis for Alnylam Pharmaceuticals.

The recent ACC.26 data and ATTR-CM care initiatives have arrived after a sharp 90 day share price return decline of 20.32%, even as the 1 year total shareholder return sits at 21.62% and the 5 year total shareholder return at 123.75%. This suggests earlier gains are now consolidating as the market reassesses risk and execution around Alnylam’s expanding cardiovascular plans.

If you are interested in how RNAi and AI are reshaping healthcare, it may be worth broadening your watchlist with 37 healthcare AI stocks

With shares retreating after a strong multi year run, but Alnylam still trading below some valuation estimates, you now have to ask: is this a reset that creates an entry point, or are expectations for future growth already fully reflected?

Most Popular Narrative: 35.2% Undervalued

With Alnylam last closing at $318.85 versus a narrative fair value of $491.92, the prevailing view prices in a sizeable valuation gap that hinges on execution and long term earnings power.

The strong track record of rapid health system integration and scalable commercial execution, with SG&A and R&D investments offset by exceptional sales growth, points to the start of meaningful operational leverage, improving net margins as product revenues outpace fixed cost escalation.
Broader long term trends of increasing rare disease prevalence and expanding healthcare/pharma spend, amplified by Alnylam's leadership in RNAi technology, position the company to benefit disproportionately from continued innovation in precision medicine, supporting enduring earnings growth and potentially leading to upward re rating of the company's stock.

Read the complete narrative.

Curious what underpins that valuation gap? The narrative focuses on rapid revenue expansion, rising profitability and a rich future earnings multiple that rivals high growth peers.

Result: Fair Value of $491.92 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on AMVUTTRA maintaining its trajectory and pricing power, with any pressure on TTR margins or payer access likely to quickly challenge that upbeat earnings path.

Find out about the key risks to this Alnylam Pharmaceuticals narrative.

Another Angle: Rich Multiples Versus “Cheap” Fair Value

Here is the catch. While the SWS model suggests Alnylam trades at a 48% discount to fair value, the current P/E of about 135x is far above the estimated fair ratio of 32.2x, the US Biotechs average of 14.9x, and the 44x peer average. This points to meaningful valuation risk if expectations slip.

That kind of gap can either compress through earnings catching up or through the share price coming back toward the fair ratio. Which outcome do you think is more realistic at $318.85?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly split between execution upside and valuation risk, it makes sense to review the data yourself, move quickly, and decide where you stand by weighing 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If Alnylam has caught your attention, do not stop there. Use powerful screeners to uncover other opportunities that could fit your goals before the crowd notices.

• Target steadier growth potential by scanning for companies with resilient financials using the 67 resilient stocks with low risk scores.
• Hunt for quality at a reasonable price by checking stocks that currently look attractively priced through the 62 high quality undervalued stocks.
• Seek overlooked opportunities with solid fundamentals by reviewing the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com